Acadia Pharmaceuticals Stock Today
| ACAD Stock | USD 16.59 0.15 0.90% |
Performance0 of 100
| Odds Of DistressLess than 9
|
ACADIA Pharmaceuticals is trading at 16.59 as of the 25th of April 2024, a -0.9 percent decrease since the beginning of the trading day. The stock's lowest day price was 16.55. ACADIA Pharmaceuticals has less than a 9 % chance of experiencing financial distress in the next few years, but has generated negative returns over the last 90 days. Equity ratings for ACADIA Pharmaceuticals are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 6th of May 2022 and ending today, the 25th of April 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 27th of May 2004 | Category Healthcare | Classification Health Care |
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California. The company has 164.77 M outstanding shares of which 11.16 M shares are presently shorted by private and institutional investors with about 4.66 trading days to cover. More on ACADIA Pharmaceuticals
Moving against ACADIA Stock
| 0.82 | XFOR | X4 Pharmaceuticals Buyout Trend | PairCorr |
| 0.78 | ELEV | Elevation Oncology Earnings Call This Week | PairCorr |
| 0.72 | NRSNW | NeuroSense Therapeutics | PairCorr |
| 0.7 | VKTX | Viking Therapeutics Potential Growth | PairCorr |
| 0.67 | CGC | Canopy Growth Corp Trending | PairCorr |
| 0.63 | ACB | Aurora Cannabis Trending | PairCorr |
| 0.55 | LLY | Eli Lilly Earnings Call This Week | PairCorr |
Follow Valuation Options Odds of Bankruptcy
Financial Report 13th of May 2024
ACADIA Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. ACADIA Pharmaceuticals' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding ACADIA Pharmaceuticals or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| CEO President | Stephen JD | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, OMX Stockholm Mid, NASDAQ Composite, NASDAQ Biotechnology, ARCA Biotechnology, Dow Jones Biotechnology, NASDAQ Composite Total, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation Analysts covering ACADIA Pharmaceuticals report their recommendations after researching ACADIA Pharmaceuticals' financial statements, talking to executives and customers, or listening in on ACADIA Pharmaceuticals' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering ACADIA Pharmaceuticals. The ACADIA consensus assessment is calculated by taking the average forecast from all of the analysts covering ACADIA Pharmaceuticals. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Financial Strength Based on the key indicators related to ACADIA Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, ACADIA Pharmaceuticals is not in a good financial situation at this time. It has a very high odds of going through financial crisis in May. Financial strength of ACADIA Pharmaceuticals is based on its profitability, leverage, liquidity, source of funds, and operating efficiency.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ACADIA Pharmaceuticals' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to ACADIA Pharmaceuticals' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand ACADIA Pharmaceuticals' financial leverage. It provides some insight into what part of ACADIA Pharmaceuticals' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ACADIA Pharmaceuticals (ACAD) is traded on NASDAQ Exchange in USA. It is located in 12830 El Camino Real, San Diego, CA, United States, 92130 and employs 597 people. ACADIA Pharmaceuticals is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 2.73 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate ACADIA Pharmaceuticals's market, we take the total number of its shares issued and multiply it by ACADIA Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. ACADIA Pharmaceuticals conducts business under Biotechnology sector and is part of Health Care industry. The entity has 164.77 M outstanding shares of which 11.16 M shares are presently shorted by private and institutional investors with about 4.66 trading days to cover.
ACADIA Pharmaceuticals currently holds about 436.35 M in cash with 16.7 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.7.
Check ACADIA Pharmaceuticals Probability Of Bankruptcy
Ownership AllocationACADIA Pharmaceuticals shows a total of 164.77 Million outstanding shares. The majority of ACADIA Pharmaceuticals outstanding shares are owned by institutions. These other corporate entities are usually referred to as non-private investors looking to acquire positions in ACADIA Pharmaceuticals to benefit from reduced commissions. Therefore, outside corporations are subject to a different set of regulations than regular investors in ACADIA Pharmaceuticals. Please pay attention to any change in the institutional holdings of ACADIA Pharmaceuticals as this could imply that something significant has changed or is about to change at the company. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.
Check ACADIA Ownership Details
ACADIA Stock Price Odds Analysis
What are ACADIA Pharmaceuticals' target price odds to finish over the current price? Based on a normal probability distribution, the odds of ACADIA Pharmaceuticals jumping above the current price in 90 days from now is about 91.17%. The ACADIA Pharmaceuticals probability density function shows the probability of ACADIA Pharmaceuticals stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days ACADIA Pharmaceuticals has a beta of 0.9199. This suggests ACADIA Pharmaceuticals market returns are highly-sensitive to returns on the market. As the market goes up or down, ACADIA Pharmaceuticals is expected to follow. Additionally, aCADIA Pharmaceuticals has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the NYSE Composite.
Based on a normal probability distribution, the odds of ACADIA Pharmaceuticals to move above the current price in 90 days from now is about 91.17 (This ACADIA Pharmaceuticals probability density function shows the probability of ACADIA Stock to fall within a particular range of prices over 90 days) .
ACADIA Stock Institutional Holders
Institutional Holdings refers to the ownership stake in ACADIA Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of ACADIA Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing ACADIA Pharmaceuticals' value.| Instituion | Recorded On | Shares | |
| Palo Alto Investors, Llc | 2023-12-31 | 2.4 M | |
| First Trust Advisors L.p. | 2023-12-31 | 1.8 M | |
| Millennium Management Llc | 2023-12-31 | 1.8 M | |
| Emerald Advisers, Llc | 2023-12-31 | 1.6 M | |
| Goldman Sachs Group Inc | 2023-12-31 | 1.6 M | |
| Pictet Asset Manangement Sa | 2023-12-31 | 1.5 M | |
| Norges Bank | 2023-12-31 | 1.4 M | |
| Jacobs Levy Equity Management, Inc. | 2023-09-30 | 1.4 M | |
| Morgan Stanley - Brokerage Accounts | 2023-12-31 | 1.4 M | |
| Baker Bros Advisors Lp | 2023-12-31 | 42.9 M | |
| Vanguard Group Inc | 2023-12-31 | 13.4 M |
ACADIA Pharmaceuticals Historical Income Statement
ACADIA Pharmaceuticals Income Statement is one of the three primary financial statements used for reporting ACADIA's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of ACADIA Pharmaceuticals revenue and expense. ACADIA Pharmaceuticals Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At present, ACADIA Pharmaceuticals' Selling General Administrative is projected to increase significantly based on the last few years of reporting. The current year's Total Revenue is expected to grow to about 762.8 M, whereas EBIT is forecasted to decline to (77 M). View More FundamentalsACADIA Stock Against Markets
Picking the right benchmark for ACADIA Pharmaceuticals stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in ACADIA Pharmaceuticals stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for ACADIA Pharmaceuticals is critical whether you are bullish or bearish towards ACADIA Pharmaceuticals at a given time. Please also check how ACADIA Pharmaceuticals' historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in ACADIA Pharmaceuticals without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Aroon Oscillator Now
Aroon OscillatorAnalyze current equity momentum using Aroon Oscillator and other momentum ratios |
| All Next | Launch Module |
ACADIA Pharmaceuticals Corporate Directors
ACADIA Pharmaceuticals corporate directors refer to members of an ACADIA Pharmaceuticals board of directors. The board of directors generally takes responsibility for the ACADIA Pharmaceuticals' affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of ACADIA Pharmaceuticals' board members must vote for the resolution. The ACADIA Pharmaceuticals board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.| Mary Gray | Independent Director | Profile | |
| Daniel Soland | Director | Profile | |
| William Wells | Independent Director | Profile | |
| Edmund Harrigan | Director | Profile |
How to buy ACADIA Stock?
Before investing in ACADIA Pharmaceuticals, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in ACADIA Pharmaceuticals. To buy ACADIA Pharmaceuticals stock, you can follow these steps:- Choose a brokerage firm: You need to select a brokerage firm to buy shares of ACADIA Pharmaceuticals. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
- Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
- Fund your account: You will need to deposit funds into your brokerage account to purchase ACADIA Pharmaceuticals stock. You can do this by transferring funds from your bank account or other investment accounts.
- Place your order: Once you have located ACADIA Pharmaceuticals stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
- Monitor your investment: After you have purchased ACADIA Pharmaceuticals stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as ACADIA Pharmaceuticals, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy ACADIA Stock please use our How to Invest in ACADIA Pharmaceuticals guide.
Already Invested in ACADIA Pharmaceuticals?
The danger of trading ACADIA Pharmaceuticals is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of ACADIA Pharmaceuticals is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than ACADIA Pharmaceuticals. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile ACADIA Pharmaceuticals is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether ACADIA Pharmaceuticals is a strong investment it is important to analyze ACADIA Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact ACADIA Pharmaceuticals' future performance. For an informed investment choice regarding ACADIA Stock, refer to the following important reports: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ACADIA Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. For information on how to trade ACADIA Stock refer to our How to Trade ACADIA Stock guide.Note that the ACADIA Pharmaceuticals information on this page should be used as a complementary analysis to other ACADIA Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..
Complementary Tools for ACADIA Stock analysis
When running ACADIA Pharmaceuticals' price analysis, check to measure ACADIA Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ACADIA Pharmaceuticals is operating at the current time. Most of ACADIA Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of ACADIA Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ACADIA Pharmaceuticals' price. Additionally, you may evaluate how the addition of ACADIA Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules |
Is ACADIA Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ACADIA Pharmaceuticals. If investors know ACADIA will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ACADIA Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.37) | Revenue Per Share 4.434 | Quarterly Revenue Growth 0.693 | Return On Assets (0.07) | Return On Equity (0.15) |
The market value of ACADIA Pharmaceuticals is measured differently than its book value, which is the value of ACADIA that is recorded on the company's balance sheet. Investors also form their own opinion of ACADIA Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is ACADIA Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ACADIA Pharmaceuticals' market value can be influenced by many factors that don't directly affect ACADIA Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ACADIA Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if ACADIA Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ACADIA Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.